Navigation Links
Tomball Regional Medical Center Selects Clinical Xpert(TM) from Thomson Reuters to Lead Quality Improvement Initiatives
Date:1/15/2009

ensive solution - in terms of features, functionality and customer support - that met our strict criteria," said Keith Barber, chief operations officer and chief financial officer for Tomball Regional Medical Center. "These are both great solutions that will give our clinicians the tools they need to enhance decision-making at the point-of-care and improve efficiency."

John Butler, director of pharmacy at Tomball, said: "Using this clinical surveillance tool, CareFocus, to monitor our patient population and help identify the high-risk patients is a tremendous resource for our staff. It will enable us to respond quicker to these patients, saving time and money.

"And having immediate access to our patient's information on our PDAs means we can spend more time on rounds treating patients - and not combing through charts searching for the relevant clinical data."

Tomball will combine clinical solutions from Thomson Reuters to develop a closed-loop quality improvement process. The medical center also uses CareDiscovery(TM), a benchmarking solution from Thomson Reuters, to analyze clinical performance and make comparisons with peer-group and national benchmarks.

"Using CareFocus and CareDiscovery together gives us a powerful, end-to-end quality improvement solution that not only enables our clinicians to take direct and immediate action to treat at-risk patients but also allows us to monitor and measure our progress on an ongoing basis," said Bonnie Brown, Tomball's director of quality improvement. "This gives us a great opportunity to make tremendous strides toward raising the standard of care across our entire facility."

About Thomson Reuters

The Healthcare business of Thomson Reuters produces insights, information, benchmarks and analysis that enable organizations to manage costs, improve performance and enhance the quality of healthcare. Thomson Reuters is t
'/>"/>

SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Jefferson Regional Medical Center Selects iSirona DeviceConX for Medical Device Integration
2. SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring
3. Doc to Dock Completes Maternal Health Wing at Kumasi South Regional Hospital in Ghana
4. Photos: Nevadas Saint Marys Regional Medical Center Raises $1.3 Million During Centennial Soiree
5. Ceasefire Broken in Democratic Republic of Congo; International Medical Corps Warns of Looming Humanitarian Catastrophe and Wider Regional Impact
6. Crisis in Congo: World Vision Begins Relief Efforts for Thousands of Displaced, Calls on Regional Leaders to Act
7. Capella University Offers New MS in Psychology Specialization in Child and Adolescent Development : Capella is the only regionally accredited online university to offer this master's specialization
8. Foundation Releases Comprehensive Regional Health Care Report Card
9. iCRco Opens Regional Branch Office In Beijing, China
10. HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference
11. Healthcare Executive Richard Peitzmeier Returns to Phoenix as Regional Sales Director of SCAN Health Plan Arizona
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4CVS Caremark Names New Chief Human Resources Officer 2Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 1Emerson Ecologics Introduces the Emerson Quality Partner 28TM 29 Program 55830 2Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 1Archi Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull Through Reporting Capabilities 55826 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 1NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 2NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 3NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 4NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus like Particle 28VLP 29 Vaccine Ca 13759 5
Other Medicine Technology:Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7